Navigation Links
Ono Enters into a New Fragment-Based Drug Discovery Agreement with Evotec
Date:3/27/2008

rters at Ono.

Forward looking statements

Information set forth in this report contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits of Evotec's products and services, the payments that Evotec may receive under its collaboration agreement with Ono, the anticipated timing and results of Evotec's clinical and pre-clinical programs, and other statements that are not historical facts. Evotec cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information as a result of risks and uncertainties. These include risks and uncertainties relating to: Evotec's ability to satisfy the research-based milestones under the agreement with Ono, Evotec's ability to complete the merger because conditions to the closing of the merger may not be satisfied; the failure to successfully integrate the businesses of Evotec and Renovis; unexpected costs or liabilities resulting from the merger; the risk that synergies from the merger may not be fully realized or may take longer to realize than expected; disruption from the merger making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; development, use and protection of intellectual property; general worldwide economic conditions and related uncertainties; future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors; and the effect of exchange rate fluctuations on international operations.

The risks included above are not exhaustive. The Registrati
'/>"/>

SOURCE Evotec AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
5. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
6. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
9. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
10. AcroMetrix Renews Contract With Group Services for Americas Blood Centers
11. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014  Invivotek L.L.C., ... is pleased to announce that its animal research ... for the Assessment and Accreditation of Laboratory Animal ... of animals in science worldwide through voluntary accreditation ... for animal care and use in 38 countries. ...
(Date:7/14/2014)... , July 14, 2014  Today, ATS Labs, ... that it acquired the assets of MicroTest Labs, Inc. ... acquisition of MTL is the first step in the ... laboratory services platform to support the medical device and ... as Accuratus Lab Services , a name that ...
(Date:7/14/2014)... July 14, 2014  Medac Pharma, Inc., a ... of new molecules and improving the effectiveness of ... Drug Administration (FDA) has approved Rasuvo™, a subcutaneous ... for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis ... 10 dosage strengths, ranging from 7.5 mg to ...
Breaking Medicine Technology:Invivotek Awarded Full AAALAC Accreditation for Excellence in Laboratory Animal Care and Use 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 3Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 2Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 3Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 4Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 5Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 6Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 7Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 8
(Date:7/14/2014)... (PRWEB) July 14, 2014 Jordan Valley ... of a new comprehensive cancer center set to open ... will be the only hospital west of I-15 in ... cancer services , Additionally, Jordan Valley Medical Center has ... and cancer treatment planning systems for radiation therapy, radiosurgery ...
(Date:7/14/2014)... 14, 2014 The report “Intelligent ... [Physical Security, Life Safety, Facility Management], IT Technologies ... & Analysis (2014 - 2019)” defines and segments ... in-depth analysis and forecasting of revenues. The report ... restraints and opportunities impacting it, along with the ...
(Date:7/14/2014)... 2014 BCC Research ( http://www.bccresearch.com ... BIOLOGY: GLOBAL MARKETS , the global synthetic biology ... billion in 2018, with a five-year compound annual ... for the fastest growing segment, with anticipated $9.7 ... products in the pharmaceutical/diagnostics, chemical, energy, and agricultural ...
(Date:7/14/2014)... 13, 2014 (HealthDay News) -- Eye tests could be ... Alzheimer,s disease, two new studies suggest. In one ... certain eye test found a significant association between levels ... and levels of the plaques in the brain. Beta-amyloid ... This type of eye test could be used ...
(Date:7/14/2014)... Amy Norton HealthDay Reporter ... adults who enjoy mentally stimulating games may have bigger brains ... The study looked at the connection between playing games ... for adults in their 50s and 60s. Researchers found ... day performed better on tests of memory and other mental ...
Breaking Medicine News(10 mins):Health News:Jordan Valley Medical Center Set to Break Ground with New $10 Million Cancer Center 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 3Health News:Eye Tests Might Help ID Alzheimer's, Studies Suggest 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3
... Two animal studies published in the journal Carcinogenesis show that ... physically active mice// that had a round the clock access ... other study found that exercise and a restricted diet had ... in the animals. ,The first study exposed mice ...
... new finding and revelation comes in the form of health ... the heart. ,The petition proposed as a model qualified health// ... (150 mL) of green tea as a source of catechins ... disease. FDA has determined that the evidence is supportive, but ...
... concern over the high maternal mortality rate in Madhya ... groups to help check the menace//. ,With 13,000 ... maternal mortality rate of the state is one of ... women's meet at the missionary-run Asha Niketan Welfare Centre ...
... which stated that doctors can give drugs to end the ... the upper house of British parliament//. The assisted dying bill ... stated that doctors can prescribe lethal drugs to patients who ... live. These drugs can be administered by the patients to ...
... have become so inadequate that students are becoming increasingly ... vital organs with each other. ,Senior doctors ... medical students are not being properly trained. ... properly trained in anatomy. According to them teaching hours ...
... percentages of undernourished children in the world, the situation ... report released Thursday//. ,"India's Integrated Child Development Services ... current malnutrition crisis," states the report "India's Undernourished Children: ... of underweight children in India is among the highest ...
Cached Medicine News:Health News:Green tea’s health claims questioned: FD 2Health News:Green tea’s health claims questioned: FD 3Health News:Malnutrition Crisis On Rise In India: World Bank 2
... The VersaPulse® PowerSuite™ holmium laser ... properties for precise, virtually bloodless procedures. ... fragmenting urinary and gall bladder stones ... ideal multipurpose surgical tool. Because its ...
... The VersaPulse® PowerSuite™ holmium laser combines ... for precise, virtually bloodless procedures. It ... urinary and gall bladder stones of ... multipurpose surgical tool. Because its laser ...
Turnstile casting stand for easy and safe casting. The compact system sets up quickly and stores conveniently, and the non-stick coating prevents fiberglass or plaster from adhering to surface....
... Cemex features a unique self-contained ... clinically proven in Europe for ... integrating bone cement powder and ... system, Cemex is designed to ...
Medicine Products: